Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | KLK1 | P06870 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13965256 | 0.87 | SIGMAR1 (0.40) | CYP11B1CYP11B2S1PR1SIGMAR1DRD2 | |
| SCHEMBL3988522 | 0.85 | DYRK1A (0.45) | CYP11B1CYP11B2KLKB1KLK1 | |
| SCHEMBL13965255 | 0.84 | MMP2 (0.39) | MMP12HTR3A | |
| SCHEMBL3984797 | 0.83 | HRH3 (0.35) | CYP11B1CYP11B2SIGMAR1CHRNA7HTR3A | |
| SCHEMBL3985158 | 0.77 | SIGMAR1 (0.48) | SIGMAR1 | |
| SCHEMBL3986058 | 0.77 | CYP2E1 (0.44) | CYP11B1CYP11B2SIGMAR1CHRNA7HTR3A | |
| SCHEMBL5228198 | 0.76 | SIGMAR1 (0.42) | CYP11B1CYP11B2SIGMAR1DRD2DRD4 | |
| SCHEMBL14528290 | 0.76 | SIGMAR1 (0.42) | CYP11B1CYP11B2SIGMAR1DRD2DRD4 | |
| SCHEMBL3989432 | 0.75 | DRD2 (0.56) | DRD2DRD4DRD3CHRNA7HTR3A | |
| SCHEMBL3991069 | 0.75 | HCRTR1 (0.41) | SIGMAR1DRD2DRD4DRD3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673372-B1 | NON-AMIDE NONANES | ASTRAZENECA AB (SE) | 2007-05-30 | — | — | EP | claimed |
| JP-2007506723-A | — | — | 2007-03-22 | — | — | JP | claimed |
| US-20070043031-A1 | 4-(thiazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; 4-(2-phenyl-imidazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; nicotinic acetylcholine receptor agonists; diagnostics; amidation of 1,4-diaza-bicyclo[3.2.2]nonane, reduction and reductive amination | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | claimed |
| EP-1673372-A1 | NON-AMIDE NONANES | AstraZeneca AB (SE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005030777-A1 | NON-AMIDE NONANES | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | claimed |
| US-7482338-B2 | Non-amide nonanes | ASTRAZENECA AB (SE) | 2009-01-27 | — | — | US | disclosed |
| US-7482338-B2 | Non-amide nonanes | ASTRAZENECA AB (SE) | 2009-01-27 | — | — | US | disclosed |
| EP-1673372-B1 | NON-AMIDE NONANES | ASTRAZENECA AB (SE) | 2007-05-30 | — | — | EP | disclosed |
| EP-1673372-B1 | NON-AMIDE NONANES | ASTRAZENECA AB (SE) | 2007-05-30 | — | — | EP | disclosed |
| US-20070043031-A1 | 4-(thiazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; 4-(2-phenyl-imidazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; nicotinic acetylcholine receptor agonists; diagnostics; amidation of 1,4-diaza-bicyclo[3.2.2]nonane, reduction and reductive amination | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| US-20070043031-A1 | 4-(thiazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; 4-(2-phenyl-imidazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; nicotinic acetylcholine receptor agonists; diagnostics; amidation of 1,4-diaza-bicyclo[3.2.2]nonane, reduction and reductive amination | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043031-A1 | 4-(thiazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; 4-(2-phenyl-imidazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; nicotinic acetylcholine receptor agonists; diagnostics; amidation of 1,4-diaza-bicyclo[3.2.2]nonane, reduction and reductive amination | CHRND, CHRNE, CHRM2 | CYP11B1 1790/4885CYP11B2 1178/4885S1PR1 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.